These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26799610)

  • 1. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
    Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
    Amin HM; Yang Y; Shen Y; Estey EH; Giles FJ; Pierce SA; Kantarjian HM; O'Brien SM; Jilani I; Albitar M
    Leukemia; 2005 Sep; 19(9):1567-72. PubMed ID: 16049515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
    Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
    Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
    Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.
    Hirst WJ; Mufti GJ
    Leuk Res; 1994 Nov; 18(11):797-804. PubMed ID: 7967705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG; Ball S; Aguirre L; Al Ali N; Kaldas D; Tinsley-Vance S; Kuykendall A; Chan O; Sweet K; Lancet JE; Padron E; Sallman DA; Komrokji R
    Haematologica; 2024 Jul; 109(7):2157-2164. PubMed ID: 38299605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
    Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
    Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
    Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
    Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
    Blood; 1997 Oct; 90(8):2969-77. PubMed ID: 9376577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.